Pharmacokinetics of CBD in osteoarthritic Dogs
Researchers evaluated the oral pharmacokinetics, and assess safety and efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).
A clinical trial with client-owned dogs presenting for evaluation and treatment of a lameness due to OA was also performed. Sixteen dogs completed the trial.
Related: Get our guide to CBD
The study was a randomized, placebo-controlled, owner and veterinarian double-blind, cross-over trial. Dogs received each of two treatments in random order: CBD, 2 mg/kg every 12 h, or placebo every 12 h. Each treatment was administered for 4 weeks with a 2-week washout period in between treatments. Blood was collected to repeat complete blood counts and chemistry analysis at weeks 2 and 4 for each treatment.
Pharmacokinetics revealed an elimination half-life of 4.2 h at both doses. Clinically, the treated dogs showed a significant decrease in pain and increase in activity with CBD oil. Veterinary assessment showed decreased pain during CBD treatment.
No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment.
The study suggests that a dose of 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA.
Read more by clicking on the link below:
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
